Differences in coagulation responses to vascular injury between uninterrupted dabigatran and apixaban: A clinical prospective randomized study.

Masaomi Chinushi, Yuki Hasegawa, Nobue Yagihara, Takayuki Inomata, Shinya Fujiki, Kenichi Iijima, Takahiro Tanaka, Daisuke Izumi, Tohru Minamino, Masahiro Ishizawa, Yasuhiro Ikami, Hirotaka Sugiura, Sou Otsuki, Naomasa Suzuki, Yuta Sakaguchi, Takahiro Hakamata

Journal: Heart rhythm 2025;22(1):21-28

PMID: 39019384

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

The coagulation response during vascular injury with uninterrupted administration of direct oral anticoagulants has not been elucidated.

OBJECTIVE

Our aim was to evaluate differences in coagulation responses after vascular injury between uninterrupted direct thrombin inhibitor and direct factor Xa inhibitor recipients.

METHODS

Patients scheduled for catheter ablation for atrial fibrillation were randomly assigned to receive dabigatran or apixaban in this prospective, randomized, comparative, parallel-group study. Venous blood was collected 3 times: 180 minutes after taking the anticoagulant on the day before the procedure, before vascular punctures of the ablation procedure, and 10-15 minutes after the start of vascular punctures.

RESULTS

Forty-two patients were enrolled. The prothrombin fragment 1+2 level, the primary end point, was much larger after vascular puncture in the uninterrupted dabigatran recipients (median, 83 pmol/L; interquartile range, 56-133 pmol/L) than in the uninterrupted apixaban recipients (median, 1 pmol/L; interquartile range, -3 to 19 pmol/L; P < .001). Antithrombin levels decreased after vascular puncture in dabigatran recipients, and both protein C and antithrombin levels decreased after vascular puncture in apixaban recipients.

CONCLUSION

Unlike uninterrupted apixaban, uninterrupted dabigatran does not inhibit thrombin generation in response to vascular injury.

Address: Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.; Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Electronic address: [email protected].; Department of Cardiovascular Medicine, Niigata Medical Center, Niigata, Japan.; Clinical and Translational Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan.; School of Health Science, Faculty of Medicine, Niigata University, Niigata, Japan.; Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

DOI: 10.1016/j.hrthm.2024.07.017

Link outs

Free resources

Medical:

https://medlineplus.gov/atrialfibrillation.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Humans, Dabigatran, Male, Female, Pyridones, Pyrazoles, Prospective Studies, Atrial Fibrillation, Middle Aged, Blood Coagulation, Aged, Vascular System Injuries, Catheter Ablation, Factor Xa Inhibitors, Benzimidazoles, beta-Alanine, Antithrombins